407 related articles for article (PubMed ID: 28247712)
1. [Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Mikhailenko DS; Nemtsova MV
Urologiia; 2016 Feb; (1):100-105. PubMed ID: 28247712
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
3. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
4. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
5. [THE SOMATIC MUTATIONS AND ABERRANT METHYLATION AS POTENTIAL GENETIC MARKERS OF URINARY BLADDER CANCER].
Mikhailenko DS; Kushlinskii NE
Klin Lab Diagn; 2016 Feb; 61(2):78-83. PubMed ID: 27455559
[TBL] [Abstract][Full Text] [Related]
6. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
[TBL] [Abstract][Full Text] [Related]
7. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer: novel molecular characteristics, diagnostic, and therapeutic implications.
Kompier LC; van Tilborg AA; Zwarthoff EC
Urol Oncol; 2010; 28(1):91-6. PubMed ID: 20123356
[TBL] [Abstract][Full Text] [Related]
9. Bladder Cancer and Genetic Mutations.
Zhang X; Zhang Y
Cell Biochem Biophys; 2015 Sep; 73(1):65-9. PubMed ID: 27352265
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
[TBL] [Abstract][Full Text] [Related]
12. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
13. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Earl J; Rico D; Carrillo-de-Santa-Pau E; Rodríguez-Santiago B; Méndez-Pertuz M; Auer H; Gómez G; Grossman HB; Pisano DG; Schulz WA; Pérez-Jurado LA; Carrato A; Theodorescu D; Chanock S; Valencia A; Real FX
BMC Genomics; 2015 May; 16(1):403. PubMed ID: 25997541
[TBL] [Abstract][Full Text] [Related]
14. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Serizawa RR; Ralfkiaer U; Steven K; Lam GW; Schmiedel S; Schüz J; Hansen AB; Horn T; Guldberg P
Int J Cancer; 2011 Jul; 129(1):78-87. PubMed ID: 20824703
[TBL] [Abstract][Full Text] [Related]
15. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer.
Czerniak B; Chaturvedi V; Li L; Hodges S; Johnston D; Roy JY; Luthra R; Logothetis C; Von Eschenbach AC; Grossman HB; Benedict WF; Batsakis JG
Oncogene; 1999 Feb; 18(5):1185-96. PubMed ID: 10022124
[TBL] [Abstract][Full Text] [Related]
16. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
Segovia C; Martínez-Fernández M; Dueñas M; Rubio C; López-Calderón FF; Costa C; Saiz-Ladera C; Fernández-Grajera M; Duarte J; Muñoz HG; de la Rosa F; Villacampa F; Castellano D; Paramio JM
Oncotarget; 2017 Feb; 8(6):10531-10542. PubMed ID: 28060766
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways of urothelial development and bladder tumorigenesis.
Castillo-Martin M; Domingo-Domenech J; Karni-Schmidt O; Matos T; Cordon-Cardo C
Urol Oncol; 2010; 28(4):401-8. PubMed ID: 20610278
[TBL] [Abstract][Full Text] [Related]
18. Bladder cancer: translating molecular genetic insights into clinical practice.
Cheng L; Zhang S; MacLennan GT; Williamson SR; Lopez-Beltran A; Montironi R
Hum Pathol; 2011 Apr; 42(4):455-81. PubMed ID: 21106220
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
20. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
van der Kwast TH; Bapat B
Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
